Drug Profile


Alternative Names: Gopten; Mavik; Nortensin; Odrik; Preran; RU 44570

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antihypertensives; Indoles
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Heart failure; Hypertension; Postmyocardial infarction

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 03 Jun 2004 Aventis granted Abbott Laboratories the remaining commercial rights for trandolapril, except in Japan
  • 19 Mar 2004 Data presented at the 53rd Annual Scientific Sessions of the American College of Cardiology (ACC-2004) have been added to the Heart Failure and Ischaemic Heart Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top